www.fdanews.com/articles/123517-3sbio-submits-application-to-china-sfda-for-feraheme-iron-therapy
3SBio Submits Application to China SFDA for Feraheme Iron Therapy
January 8, 2010
3SBio Inc. announced that it has submitted its application for a registrational clinical trial to the Chinese State Food and Drug Administration (“SFDA”)
for Feraheme (ferumoxytol) Injection for intravenous use.
StreetInsider
StreetInsider